SpaceX Prices Biggest Ever IPO At $135 Per Share While there was little doubt as to SpaceX's actual IPO price, which due to its novel structure was always going to be $135, and unlike the proposed IPO price ranges as is customary for other initial offerings, moments ago SpaceX (SPCX) made it official when it filed a free writing prospectus (FWP) which confirmed the company sold 555.6 million share...
SpaceX Prices Biggest Ever IPO At $135 Per Share While there was little doubt as to SpaceX's actual IPO price, which due to its novel structure was always going to be $135, and unlike the proposed IPO price ranges as is customary for other initial offerings, moments ago SpaceX (SPCX) made it official when it filed a free writing prospectus (FWP) which confirmed the company sold 555.6 million shares at $135 each, for a total size of $75 billion (excluding the greenshoe), making history with the biggest-ever IPO, launching it into the top ranks of the largest public companies and putting founder Elon Musk on the verge of becoming the world’s first trillionaire. For context, SpaceX is more than double the size of the previous largest IPO - Saudi Aramco’s $29.4 billion listing in 2019. The SpaceX registration statement was declared effective June 11. The details of the pricing are shown below. At $135, SpaceX will have a market value of $1.77 trillion. Accounting for employee stock options and restricted share units, the pricing gives it a fully diluted valuation of about $1.8 trillion. SpaceX’s market value will rank it among the top 10 public companies globally, and make it larger even than Musk’s own Tesla. According to Polymarket, there is a 84% chance the IPO closes above its offering price tomorrow, and a 46% chance it rises more than 20%. Nearly 50% odds on Polymarket that SPCX rises 20% ($2.2TN market cap) on its first day of trading, and 84% odds it closes above its offering price. https://t.co/UfN4FOlP7T pic.twitter.com/6U0S0HDyt1 — zerohedge (@zerohedge) June 11, 2026 SpaceX, which made a net loss of $4.9bn in 2025, is made up of three businesses: space exploration, including its Falcon and Starship rockets; connectivity, such as its Starlink satellite constellation providing high-speed internet access; and artificial intelligence, though its xAI division. Musk’s fan base in the retail trading community is a crucial component of the deal: they have placed mor...
Advanced Micro Devices (AMD) investors have had little to celebrate this month. The chipmaker’s shares fell 4.86% on June 10 to close at $452.40, stretching the loss over the past five trading days to 12.15%. The selling was not an AMD problem, as a wave of profit-taking and Middle East tensions ...
Advanced Micro Devices (AMD) investors have had little to celebrate this month. The chipmaker’s shares fell 4.86% on June 10 to close at $452.40, stretching the loss over the past five trading days to 12.15%. The selling was not an AMD problem, as a wave of profit-taking and Middle East tensions ...
Unusual Machines (NYSEMKT: UMAC) stock jumped 13.1% through 3:30 p.m. ET Thursday after Needham analyst Austin Bohlig raised his price target on the drone stock by 36%, to $30 per share. Image source: Getty Images. Demand for U.S.-produced drone components "continues to far exceed available supply," reports Needham -- and is still growing. As the only (that I know of) pure-play, publicly traded su...
Unusual Machines (NYSEMKT: UMAC) stock jumped 13.1% through 3:30 p.m. ET Thursday after Needham analyst Austin Bohlig raised his price target on the drone stock by 36%, to $30 per share. Image source: Getty Images. Demand for U.S.-produced drone components "continues to far exceed available supply," reports Needham -- and is still growing. As the only (that I know of) pure-play, publicly traded supplier of low-cost drone parts based in the United States, Unusual Machines is a likely primary beneficiary of U.S. legislation that, since December last year, has banned the import of critical drone components from foreign sources. Continue reading
SpaceX has made history with the biggest-ever IPO, selling 555.6 million shares at $135 each, and has a market value of $1.77 trillion. Trading is set to begin on the Nasdaq Friday. Elon Musk could now become the world's first trillionaire. Ed Ludlow has all the breaking details. (Source: Bloomberg)
SpaceX has made history with the biggest-ever IPO, selling 555.6 million shares at $135 each, and has a market value of $1.77 trillion. Trading is set to begin on the Nasdaq Friday. Elon Musk could now become the world's first trillionaire. Ed Ludlow has all the breaking details. (Source: Bloomberg)
Amphenol (NYSE:APH) is a stock built to be owned for decades, because every meaningful electronics megatrend of the next twenty years (AI infrastructure, defense modernization, vehicle electrification, factory automation) physically depends on the connectors, sensors, and cables it sells. For a retirement-focused investor who wants to stop watching the screen, Amphenol is the rare industrial ... G...
Amphenol (NYSE:APH) is a stock built to be owned for decades, because every meaningful electronics megatrend of the next twenty years (AI infrastructure, defense modernization, vehicle electrification, factory automation) physically depends on the connectors, sensors, and cables it sells. For a retirement-focused investor who wants to stop watching the screen, Amphenol is the rare industrial ... Got $1,500? This Invisible Megatrend Makes 1 Serial Compounder a Clear Buy Right Now
A new stock split is coming in a few weeks, and it's coming from an unlikely source: CrowdStrike (NASDAQ: CRWD) . This isn't one I had on my radar, as its stock price in the neighborhood of $650 isn't quite at a level you'd normally associate a split with. Still, management will enact a 4-for-1 stock split at the end of the trading day on July 1. This will be a major event for some investors, but ...
A new stock split is coming in a few weeks, and it's coming from an unlikely source: CrowdStrike (NASDAQ: CRWD) . This isn't one I had on my radar, as its stock price in the neighborhood of $650 isn't quite at a level you'd normally associate a split with. Still, management will enact a 4-for-1 stock split at the end of the trading day on July 1. This will be a major event for some investors, but I think there are better reasons to buy the stock. I've got three reasons why CrowdStrike is a solid buy before its stock split, and why investors should view its sell-off this month as a buying opportunity. Image source: Getty Images. Continue reading
Andrzej Rostek/iStock via Getty Images The last time I spoke about Nuvalent ( NUVL ) it was with a Seeking Alpha article entitled " Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases ." With respect to this article, I mentioned that the company had achieved positive results from the phase 1/2 ALKOVE-1 study using its 4th-generation selective tyrosine kinase inhibitor ...
Andrzej Rostek/iStock via Getty Images The last time I spoke about Nuvalent ( NUVL ) it was with a Seeking Alpha article entitled " Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases ." With respect to this article, I mentioned that the company had achieved positive results from the phase 1/2 ALKOVE-1 study using its 4th-generation selective tyrosine kinase inhibitor [TKI] neladalkib [NVL-655] for the treatment of patients with ALK-positive non-small cell lung cancer. I also mentioned that the company was working on its other selective TKI zidesamtinib [NVL-520] for the treatment of patients with ROS1-positive NSCLC from the phase 1/2 ARROS-1 study. The latest update is that the company was able to achieve positive results from both of these late-stage pivotal programs. As a matter of fact, it was able to submit New Drug Applications [NDAs] for both neladalkib and zidesamtinib for the treatment of patients with ALK-positive and ROS1-positive NSCLC, respectively. A Prescription Drug User Fee Act [PDUFA] date of September 18, 2026, was set up to review zidesamtinib for the treatment of ROS1-positive locally advanced or metastatic NSCLC patients who were previously treated with at least one prior ROS1 TKI therapy. Then, a PDUFA date of November 27, 2026, was set up so that the FDA could decide whether or not neladalkib could be approved for TKI-pretreated advanced ALK-positive NSCLC patients. I had a "Strong Buy" rating on this stock the last time around. Today, I'm going to give this stock a "Hold" rating. Not because progress wasn't made, but because further upside is capped based on the current stock price. The reason why is because it was announced that GlaxoSmithKline ( GSK ) would pay about $10.6 billion to acquire Nuvalent in order to obtain its selective TKIs. This deal, which is expected to close in Q3 2026, might help this big pharma build out its oncology pipeline. What I want to go over below would be the positive data obtained...
A decade-old renewable energy dispute has collided with the biggest sporting event on earth, putting Madrid's logistical footprint under federal scrutiny.
A decade-old renewable energy dispute has collided with the biggest sporting event on earth, putting Madrid's logistical footprint under federal scrutiny.
Paperkites/iStock via Getty Images Alico, Inc. ( ALCO ) has moved beyond its old role as just a Florida citrus producer. The company is now becoming a land monetization story, supported by agricultural leasing, asset sales, a cleaner balance sheet, and long-term development optionality. I like the strategic pivot because management is no longer trying to defend a structurally damaged citrus model....
Paperkites/iStock via Getty Images Alico, Inc. ( ALCO ) has moved beyond its old role as just a Florida citrus producer. The company is now becoming a land monetization story, supported by agricultural leasing, asset sales, a cleaner balance sheet, and long-term development optionality. I like the strategic pivot because management is no longer trying to defend a structurally damaged citrus model. However, after the stock’s strength following the Q2 2026 update, I believe much of the near-term improvement is already reflected in the price. Business Quality: Land Value Hidden Behind A Broken Citrus Model Alico is an agribusiness company based in Florida, with more than 125 years of operating history under its belt. Over the years, the primary view investors had when analyzing the firm was that of its ability to grow citrus production. Such views are now obsolete. Following the 2025 strategic pivot , the company has begun phasing out its legacy citrus fruit farming practices and moving forward as a diverse land firm engaged in agricultural leasing, selling land, and developing its real estate potential. From an economic perspective, such a move makes sense. The firm has experienced a severe decline in citrus production over the past decade due to a series of issues. According to the CEO of the firm, citrus fruit production has dropped by 73% since the company's peak over the past ten years despite investments in land, trees, and treating diseases. Such issues as citrus greening, hurricane damage, and poor volume make for a problematic business model. In early 2025, management announced that there will be no more capital allocation to citrus fruit production and that Alico will now be exploring the highest and best use for its land. That is the main idea behind the pivot. Alico is not trying to fix a business model that is fundamentally flawed. The firm is looking to capitalize on its unique land base, which the market may have previously undervalued by viewing Alico m...
MTStock Studio/E+ via Getty Images Accounting firm Crowe has agreed to sell a stake to KKR & Co. ( KKR ). KKR ( KKR ) and co-investors will take a majority stake in Crowe, while Crowe partners will retain a minority stake in a deal valued at almost $3 billion, according to a WSJ report on Thursday, which cited people familiar with the matter. The companies said they expect the transaction to close...
MTStock Studio/E+ via Getty Images Accounting firm Crowe has agreed to sell a stake to KKR & Co. ( KKR ). KKR ( KKR ) and co-investors will take a majority stake in Crowe, while Crowe partners will retain a minority stake in a deal valued at almost $3 billion, according to a WSJ report on Thursday, which cited people familiar with the matter. The companies said they expect the transaction to close in Q3, though they declined to comment on the valuation and stake size, according to the report. More on KKR & Co. KKR & Co. Inc. (KKR) Presents at Morgan Stanley US Financials Conference 2026 - Slideshow KKR & Co. Inc. (KKR) Presents at Morgan Stanley US Financials Conference 2026 Transcript KKR & Co. Inc.: 7%+ Investment-Grade From Its Baby Bonds KKR, Nvidia, Vistra, Kuwait Investment Authority launch infrastructure company for hyperscalers DCC says it supports revised $7.6B buyout proposal from KKR-led consortium
Rpsycho/iStock via Getty Images I cashed out of my final Oracle Corporation ( ORCL ) holdings before the earnings report using a trailing stop and locked in a +50.5% gain on the final lot. Since my last ORCL analysis, the stock has lost nearly 30% in price. In that thesis, I stated that it was wise to profit from others' speculation and to stick to intrinsic value . My rating at the time essential...
Rpsycho/iStock via Getty Images I cashed out of my final Oracle Corporation ( ORCL ) holdings before the earnings report using a trailing stop and locked in a +50.5% gain on the final lot. Since my last ORCL analysis, the stock has lost nearly 30% in price. In that thesis, I stated that it was wise to profit from others' speculation and to stick to intrinsic value . My rating at the time essentially nailed the short-term top perfectly. Oracle's Q4 results were strong in essence, with revenue up by 21%, cloud revenue up by 47%, OCI revenue up by 93%, and remaining performance obligations ("RPO") up by 363%. But the question on the market's mind appears to be whether Oracle can build capacity fast enough, preserve margins, and fund the capex cycle sustainably without major setbacks and valuation resets. FY26 operating cash flow was a record $32.0B, but free cash flow was negative at -$23.7B because the OCI buildout is so capital intensive. The company also remains debt-heavy, with the company raising $43B of debt and $5B of equity in FY26. It also expects to raise $40B in FY27, including its previously announced $20B at-the-market equity issuance. Oracle's AI demand is clear... but I don't think the balance sheet risk should just be glossed over. If AI capex digestion slows the conversion of remaining performance obligations, then leverage, dilution, and depreciation have the potential to outrun returns. The primary long-term bottleneck would show up in funding capacity before cash realization, which could set Oracle far behind cash-rich hyperscalers like Microsoft ( MSFT ). That's why I hold MSFT at about 10% of NAV and ORCL at only 3% for now. Oracle's Valuation Resets, And The Pros Return To The Table Oracle One-Day-Intervals Price Chart (Author's Chart) After trading well above the 200-day moving average in price for a moment, the stock has now retraced to below the 50-day moving average. Once again, the equity looks more fairly priced, and I'm re-entering and tra...
Rpsycho/iStock via Getty Images I cashed out of my final Oracle Corporation ( ORCL ) holdings before the earnings report using a trailing stop and locked in a +50.5% gain on the final lot. Since my last ORCL analysis, the stock has lost nearly 30% in price. In that thesis, I stated that it was wise to profit from others' speculation and to stick to intrinsic value . My rating at the time essential...
Rpsycho/iStock via Getty Images I cashed out of my final Oracle Corporation ( ORCL ) holdings before the earnings report using a trailing stop and locked in a +50.5% gain on the final lot. Since my last ORCL analysis, the stock has lost nearly 30% in price. In that thesis, I stated that it was wise to profit from others' speculation and to stick to intrinsic value . My rating at the time essentially nailed the short-term top perfectly. Oracle's Q4 results were strong in essence, with revenue up by 21%, cloud revenue up by 47%, OCI revenue up by 93%, and remaining performance obligations ("RPO") up by 363%. But the question on the market's mind appears to be whether Oracle can build capacity fast enough, preserve margins, and fund the capex cycle sustainably without major setbacks and valuation resets. FY26 operating cash flow was a record $32.0B, but free cash flow was negative at -$23.7B because the OCI buildout is so capital intensive. The company also remains debt-heavy, with the company raising $43B of debt and $5B of equity in FY26. It also expects to raise $40B in FY27, including its previously announced $20B at-the-market equity issuance. Oracle's AI demand is clear... but I don't think the balance sheet risk should just be glossed over. If AI capex digestion slows the conversion of remaining performance obligations, then leverage, dilution, and depreciation have the potential to outrun returns. The primary long-term bottleneck would show up in funding capacity before cash realization, which could set Oracle far behind cash-rich hyperscalers like Microsoft ( MSFT ). That's why I hold MSFT at about 10% of NAV and ORCL at only 3% for now. Oracle's Valuation Resets, And The Pros Return To The Table Oracle One-Day-Intervals Price Chart (Author's Chart) After trading well above the 200-day moving average in price for a moment, the stock has now retraced to below the 50-day moving average. Once again, the equity looks more fairly priced, and I'm re-entering and tra...